Pharmaceutical Marking another approval for the drug in the country, Anglo-Swedish pharma major AstraZeneca has received approval in China for Tagrisso (osimertinib) for the adjuvant treatment of patients with early-stage (IB, II and IIIA) epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) after tumor resection with curative intent, with or without adjuvant chemotherapy as recommended by the patient’s physician. 14 April 2021